NEW YORK, Jan. 23, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on GILD, IMGN, INCY, and INFI which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, January 22, 2018, the NASDAQ Composite ended the
Foster City, California headquartered Gilead Sciences Inc.'s stock finished Monday's session 0.53% higher at $81.41 with a total trading volume of 7.34 million shares. The Company's shares have advanced 14.65% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 9.23% and 10.98%, respectively. Additionally, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle-East, have a Relative Strength Index (RSI) of 72.16.
On January 16th, 2018, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Get the full research report on GILD for free by clicking below at: www.wallstequities.com/registration/?symbol=GILD
On Monday, shares in Waltham, Massachusetts headquartered ImmunoGen Inc. recorded a trading volume of 3.48 million shares, which was above its three months average volume of 2.90 million shares. The stock ended the session 6.48% higher at $8.55. The Company's shares have advanced 33.18% in the last month, 38.57% in the previous three months, and 251.85% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 31.80% and 44.39%, respectively. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have an RSI of 76.45. Get access to our top-rated research, including the free report on IMGN at: www.wallstequities.com/registration/?symbol=IMGN
Wilmington, Delaware headquartered Incyte Corp.'s shares closed the day 0.99% higher at $94.08. The stock recorded a trading volume of 2.64 million shares, which was above its three months average volume of 1.69 million shares. The stock is trading below its 50-day moving average by 3.87%. Additionally, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the US and internationally, have an RSI of 46.36.
On January 02nd, 2018, research firm RBC Capital Markets upgraded the Company's stock rating from 'Sector Perform' to 'Outperform'. Click here to subscribe for a free membership which welcomes you with our report on INCY at: www.wallstequities.com/registration/?symbol=INCY
Shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. finished 7.35% higher at $2.19. The stock recorded a trading volume of 996,276 shares. The Company's shares have advanced 17.11% in the last month. The stock is trading above its 50-day and 200-day moving averages by 7.33% and 24.68%, respectively. Furthermore, shares of Infinity Pharma, which develops medicines for patients with difficult-to-treat diseases in the US, have an RSI of 56.93. Join our big investor community at Wall St. Equities today and get your free report on INFI at: www.wallstequities.com/registration/?symbol=INFI
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----gilead-sciences-immunogen-incyte-and-infinity-pharma-300586559.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...View All